LONHALA® MAGNAIR® (glycopyrrolate) for Health Care Professionals

According to GOLD, randomized trials have not identified superiority of one device/formulation.1

For patients in need of another option, there's LONHALA MAGNAIR

LONHALA® MAGNAIR® Device

 

LONHALA MAGNAIR is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

Please see Important Safety Information below and full Prescribing Information and Patient Information for LONHALA MAGNAIR.

DEVICE FEATURES

Patients use their natural breathing to take treatment

Patients use their natural breathing to take treatment2

Virtually silent administration

Virtually silent administration4

 

2-3 minute administration

Fine, flowing mist administered in 2-3 minutes (with proper assembly and cleaning)2,3*

All within a small, portable, and battery-operated device

All within a small, portable, and battery-operated device2†

 
DEVICE FEATURES
 

Patients use their natural breathing to take treatment

Patients use their natural breathing to take treatment2

 

Device specific challenges - required setup and maintenance

Virtually silent administration4

 

LONHALA MAGNAIR COPD Device has a 2-3 minute administration time

Fine, flowing mist administered in 2-3 minutes (with proper assembly and cleaning)2,3*

 

LONHALA MAGNAIR COPD Device is portable

All within a small, portable, and battery-operated device2†

 

According to GOLD, randomized trials have not identified superiority of one device/formulation.1

GOLD does not endorse any specific treatments.

*Improper cleaning and maintenance may increase administration time.2
Handset is 2.4 x 4.7 inches. Controller is 1.6 x 4.6 inches. MAGNAIR weighs 10.2 ounces (including batteries).2

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as a rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist. 

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

GOLD=Global Initiative for Chronic Obstructive Lung Disease.


References:
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2019:1-139.
2. LONHALA MAGNAIR [manufacturer’s instructions for use]. Marlborough, MA: Sunovion Pharmaceuticals Inc.
3. Pham S, Ferguson GT, Kerwin E, Godin T, Wheeler A, Bauer A. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. [published online ahead of print Nov 10, 2017]. J Aerosol Med Pulm Drug Delivery. doi:10.1089/jamp.2017.1384.
4. Data on file. PARI. Test report: loudness measurement eLete. November 30, 2017.

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.